Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 18/20 | 0.51 |
| ▸ | MEN1 | O00255 | 17/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 17/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.51 |
| ▸ | HPGD | P15428 | 6/20 | 0.51 |
| ▸ | GAA | P10253 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2832310 | 0.98 | MAPT (0.49) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL2833137 | 0.88 | PI4KB (0.52) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL2831609 | 0.86 | PI4KB (0.50) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL2836063 | 0.85 | PIK3CG (0.46) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL2831604 | 0.85 | PI4KB (0.49) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL16872675 | 0.84 | MAPT (0.46) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL2831368 | 0.82 | PIK3CG (0.64) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL16872688 | 0.82 | PI4KB (0.46) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL2840523 | 0.79 | PI4KB (0.48) | MAPTMEN1KMT2AALDH1A1CFTR | |
| SCHEMBL2836982 | 0.78 | LMNA (0.45) | MAPTMEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888546-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2015-07-08 | — | — | EP | claimed |
| US-7799814-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2010-09-21 | — | — | US | claimed |
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | LABORATOIRES SERONO SA (CH) | 2008-08-07 | — | — | US | claimed |
| EP-1888546-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2015-07-08 | — | — | EP | disclosed |
| EP-1888546-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2015-07-08 | — | — | EP | disclosed |
| US-7799814-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799814-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799814-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | LABORATOIRES SERONO SA (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | LABORATOIRES SERONO SA (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | LABORATOIRES SERONO SA (CH) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188531-A1 | Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial, viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries | PDGFRA, PDGFRB, PF4 | MAPT 1347/4885MEN1 2916/4885KMT2A 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.